Parameter
| Biomarker | Circulating Tumor DNA (ctDNA) | Full name | Circulating Tumor DNA | Molecular Type | Nucleic acid (DNA) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, prognosis, and monitoring | ||
| Disease | Gastric Cancer | Disease Subtypes | / | ||
| Organ | Stomach | Test Sample / Technology Platform | Peripheral blood (NGS, digital PCR) | ||
| Pathobiological Mechanisms | DNA fragments released into peripheral blood by apoptosis/necrosis of tumor cells carrying tumor-specific mutations (such as TP53, KRAS, PIK3CA) can be used for early diagnosis of gastric cancer, dynamic monitoring of tumor load, prediction of recurrence and drug resistance | ||||
| Clinical Availability Status | Clinical research stage: early diagnosis and minimal residual disease (MRD) monitoring are in phase II/III clinical practice, and some are used for drug resistance detection of advanced gastric cancer | ||||
| Notes and Dynamics | The "gold standard" of liquid biopsy, MRD monitoring can detect minimal residual disease early after surgery (3-6 months earlier than imaging), dynamic monitoring of ctDNA mutations (such as TP53 and PIK3CA) can guide the adjustment of treatment plan, and standardized detection procedures (such as detection Panel and minimum detection limit) are the key to clinical transformation | ||||